

SalvaRx Group plc

("SalvaRx" or the "Company")

Delay to iOx development programme

SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that its 57% owned subsidiary, iOx Therapeutics Limited ("iOx"), has experienced a significant delay in manufacturing its lead drug candidate IMM60.

Due to quality failures in the manufacturing process that led to a batch failure, iOx is revising its timeline to dosing its first human in clinical trials. The company is confident that its process is robust and that it will move the programme forward in due course. Release of the product required for the initiation of human dosing is now likely to be in late 2019.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

-Ends-

SalvaRx Group plc

Ian Walters (Chief Executive)

Tel: +1 203 441 5451

Northland Capital Partners Limited

Tel: +44 (0) 20 3861 6625

Nominated Adviser and Broker

Matthew Johnson / Edward Hutton (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Peterhouse Corporate Finance Limited

Tel: +44 (0) 20 7469 0932

Joint Broker

Lucy Williams / Duncan Vasey

For more information please visit: www.salvarx.io